The second dose will be considered when there is more knowledge from other countries that have come further in the vaccination of this age group.” “We consider that the offer of one dose provides the clearest benefit for the individual adolescent when the benefit is weighed against possible disadvantages of the vaccine. “One dose provides good protection against a severe disease course, and the protection will probably be better among adolescents at this age than for older age groups,” says Camilla Stoltenberg, Director-General of the Norwegian Institute of Public Health in a release. “Some minor difference in the chemical composition of the two vaccines may have contributed to this so-called risk even though they are both mRNA vaccines, they are not identical.” He also mentions the higher dosage of 100 microgram used in the Moderna vaccine compared with 30 microgram for Pfizer might be another possibility. “The two vaccines have not been used in the same populations, and there may well be differences in the people who have received one versus the other which could contribute to this so-called difference in risk (rather than the vaccine),” says Dr. Satyajit Rath, formerly with the Delhi-based National Institute of Immunology says in an email that since the serious adverse events are extremely rare it is not even absolutely certain that there is really an increase in this ‘risk’ of myocarditis with the Moderna vaccine over the Pfizer vaccine. On why the Moderna vaccine has a relatively increased risk of myocarditis and pericarditis after the second dose compared with Pfizer, Immunologist Dr. Meanwhile, the U.K., Hong Kong and Norway, have recommended administering only a single dose of the Pfizer vaccine for children aged 12 years and older. For an individual, the risk of being affected by myocarditis and pericarditis is small. The Swedish Public Health Agency said that the connection is “especially clear when it comes to Moderna vaccine Spikevax, especially after the second dose”. “A Nordic study involving Finland, Sweden, Norway and Denmark found that men under the age of 30 who received Moderna Spikevax had a slightly higher risk than others of developing myocarditis,” Mika Salminen, director of the Finnish Institute for Health and Welfare told The Swedish Agency said its decision is valid till December 1 this year.
Both Finland Health institute and the Swedish Public Health Agency now recommend Pfizer’s mRNA vaccine for people younger than 30 years as there is greater experience with the vaccine in this age group. Myocarditis causes inflammation of heart muscle which can limit the organ’s ability to pump blood and can cause changes in heartbeat rhythms, while pericarditis causes inflammation of the outer lining of the heart.Ī day later, Finland followed suit and paused the use of the Moderna vaccine in people younger than 30 years. The European Medicines Agency approved the use of Comirnaty in May, while Spikevax was given the nod for children over 12 in July.On October 6, Sweden and Denmark suspended the use of Moderna’s mRNA vaccine for younger age groups after reports pointed to an increase in the number of myocarditis and pericarditis cases. People born in 1991 or later that had received a first Moderna shot, some 81,000 people, would not get a second Moderna jab, it added.Įarlier this week the Swedish health agency said people aged 12 to 15 would only get the Pfizer/Biontech vaccine. The health agency said it now recommended the Comirnaty vaccine from Pfizer/Biontech instead. “The connection is especially clear when it comes to Moderna’s vaccine Spikevax, especially after the second dose,” it said in a statement,” adding the risk of being affected was very small. Myocarditis is an inflammation of the heart muscle pericarditis is swelling and irritation of the thin, saclike tissue surrounding the heart. The health agency said data pointed to an increase of myocarditis and pericarditis among youths and young adults that had been vaccinated.
Sweden will pause the use of Moderna’s Covid-19 vaccine for people born in 1991 and later after reports of possible rare side effects, such as myocarditis, the Swedish health agency said on Wednesday.
0 kommentar(er)
